The role of proteomics in depression research.
Depression is a severe neuropsychiatric disorder affecting approximately 10% of the world population. Despite this, the molecular mechanisms underlying the disorder are still not understood. Novel technologies such as proteomic-based platforms are beginning to offer new insights into this devastating illness, beyond those provided by the standard targeted methodologies. Here, we will show the potential of proteome analyses as a tool to elucidate the pathophysiological mechanisms of depression as well as the discovery of potential diagnostic, therapeutic and disease course biomarkers.
Martins-de-Souza
Daniel
D
Max Planck Institute for Psychiatry, Kraepelinstr. 2, 80804, Munich, Germany.
Harris
Laura W
LW
Guest
Paul C
PC
Turck
Christoph W
CW
Bahn
Sabine
S
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D015415:Biomarkers; D015283:Citalopram / Q000494:pharmacology; D003866:Depressive Disorder / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D004351:Drug Resistance; D006801:Humans; D051379:Mice; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D020543:Proteome / Q000032:analysis / Q000235:genetics / Q000502:physiology; D040901:Proteomics / Q000379:methods*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
D000928:Antidepressive Agents; D015415:Biomarkers; D015283:Citalopram; D020543:Proteome; D017367:Selective Serotonin Reuptake Inhibitors